Novo Nordisk A/S
NOVO-B
Hisse Senetlerindeki Sıralama
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Hisse Fiyatı
$39.53
Piyasa Değeri
$174.45B
Değişim (1 gün)
0.75%
Değişim (1 yıl)
-25.98%
Ülke
DK
Ticaret Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
Novo Nordisk A/S (NOVO-B) için kazanç
Dec 2025 itibarıyla kazanç TTM: $20.51B
Novo Nordisk A/S şirketinin en son finansal raporlarına göre, mevcut kazancı $20.51B'dir. 2024 yılında şirket $17.75B kazanç elde etti, bu 2023 yılındaki $15.50B kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Novo Nordisk A/S için kazanç geçmişi 2001 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $20.51B | 0.00% |
| 2025 | $20.51B | 15.55% |
| 2024 | $17.75B | 14.50% |
| 2023 | $15.50B | 55.92% |
| 2022 | $9.94B | 10.02% |
| 2021 | $9.03B | 3.59% |
| 2020 | $8.72B | 19.69% |
| 2019 | $7.29B | -0.35% |
| 2018 | $7.31B | -6.79% |
| 2017 | $7.84B | 15.64% |
| 2016 | $6.78B | 7.06% |
| 2015 | $6.34B | 14.26% |
| 2014 | $5.55B | -7.59% |
| 2013 | $6.00B | 22.00% |
| 2012 | $4.92B | 28.80% |
| 2011 | $3.82B | 16.43% |
| 2010 | $3.28B | 21.42% |
| 2009 | $2.70B | 13.54% |
| 2008 | $2.38B | 10.14% |
| 2007 | $2.16B | 33.54% |
| 2006 | $1.62B | 24.30% |
| 2005 | $1.30B | -5.19% |
| 2004 | $1.37B | 6.85% |
| 2003 | $1.28B | 44.62% |
| 2002 | $888.11M | 23.73% |
| 2001 | $717.79M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $33.60B | 63.84% |
US
|
|
| $17.74B | -13.50% |
US
|
|
| $8.70B | -57.58% |
US
|
|
| $5.95B | -70.99% |
US
|
|
| $21.39B | 4.31% |
CH
|
